Navigation Links
NexGen Biomedical, Inc. Provides New Insights Into Jett Travolta's Seizure Related Death
Date:6/12/2012

SAN JOSE, Calif., June 12, 2012 /PRNewswire/ -- US patent 8,197,858 issued on June 12, 2012 discloses a previously unknown pathogenesis underlying seizures / epilepsy and migraines and provides novel treatment options for the 50 million seizure patients and 300 million migraine sufferers worldwide.

"We scientifically validated that triggers such as drops in estrogen or testosterone or increases in prostaglandin or Vitamin D synthesis all boost release of calcium ions from bone.  We also validated that boosting extracellular calcium ion levels boosts seizure and migraine risk by 1) depolarizing nerve membranes, 2) increasing calcium channel mediated neurotransmitter release and 3) boosting muscle contractility,"  according to Mark Zamoyski,  NexGen Biomedical, Inc.'s founder and the patent holder.

"Why 50 million people worldwide have low seizures thresholds is not clear, however, the new pathogenesis provides an insight into factors that would increase their risk of having a seizure,"  continued Mark Zamoyski.  "We can begin to understand the perfect storm of risk factors that possibly contributed to 16 year old Jett Travolta's uncontrollable seizure while on a vacation in the Bahamas.  Puberty brings nighttime testosterone surges, followed by daytime drops, which boost calcium ion release from bone.   Sun exposure can boost Vitamin D synthesis to 25 times the RDA and sunburn boosts prostaglandin synthesis, both of which boost release of calcium from bone and hence boost seizure risk.  And those are just some of the risk factors on the list."

"Previously unexplained migraine observations could now also be explained. As an example, one study found 45% of women with menstrual migraines had magnesium deficiency.  The new pathogenesis explanation:  It is known that estrogen levels drop precipitously at the start of menstruation.  That in turn would result in a boost in extracellular calcium levels.   Magnesium is a physiological calcium channel blocker, which would attenuate the calcium channel mediated neurotransmitter release."

"Basically, the science indicates that anything that boosts release of calcium ions from bone boosts seizure and migraine risk and conversely anything that reduces release of calcium ions from bone reduces seizure and migraine risk.  Fortunately, there are existing bone homeostasis drugs that could be easily repurposed to reduce seizure and migraine risk,"  Mark Zamoyski summarized.

More comprehensive data supporting the pathogenesis, and a list of things that increase or decrease release of calcium ions from bone, is provided at www.nexgen.biz.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
2. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
3. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
4. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
7. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
8. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
9. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
10. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
11. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):